Vir Biotechnology

Vir Biotechnology, Inc. is an immunology company dedicated to harnessing the power of the immune system to address unmet patient needs in infectious diseases and beyond. The company combines its proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities to engineer a rich database of human antibodies, delivering transformative medicines for diseases with significant global burden.

Vir's current pipeline includes multiple clinical candidates targeting hepatitis B and hepatitis delta viruses, as well as human immunodeficiency virus (HIV). This includes a potential functional cure for chronic hepatitis B and treatments for chronic hepatitis delta. Additionally, the company is developing broad, potent investigational monoclonal antibodies targeting influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus, and human papillomavirus. Vir is also working on an investigational T cell vaccine aimed at preventing HIV.

The company collaborates with leading industry players, government agencies, and non-profit organizations to rapidly advance cutting-edge scientific discoveries and innovative technologies. These collaborations enable Vir to bring potential benefits to people around the world.

Vir Biotechnology was ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. The company is committed to transforming lives through its mission and ensuring the privacy and security of its job candidates.

Keywords: immunology, monoclonal antibodies, infectious diseases, hepatitis B, hepatitis delta, HIV, influenza, COVID-19, T cell vaccine, AI.